Primary sclerosing cholangitis: refinement and validation of survival models
- PMID: 1451982
- DOI: 10.1016/0016-5085(92)91449-e
Primary sclerosing cholangitis: refinement and validation of survival models
Abstract
The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.
Similar articles
-
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.Hepatology. 1989 Oct;10(4):430-6. doi: 10.1002/hep.1840100406. Hepatology. 1989. PMID: 2777204
-
Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis.Hepatology. 2002 Mar;35(3):652-7. doi: 10.1053/jhep.2002.31872. Hepatology. 2002. PMID: 11870380
-
A revised natural history model for primary sclerosing cholangitis.Mayo Clin Proc. 2000 Jul;75(7):688-94. doi: 10.4065/75.7.688. Mayo Clin Proc. 2000. PMID: 10907383
-
Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?Liver Transpl Surg. 1998 Sep;4(5 Suppl 1):S9-17. Liver Transpl Surg. 1998. PMID: 9742489 Review.
-
Etiology and natural history of primary sclerosing cholangitis.J Hepatobiliary Pancreat Surg. 1999;6(4):343-51. doi: 10.1007/s005340050128. J Hepatobiliary Pancreat Surg. 1999. PMID: 10664279 Review.
Cited by
-
Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.Medicine (Baltimore). 2016 Apr;95(17):e3510. doi: 10.1097/MD.0000000000003510. Medicine (Baltimore). 2016. PMID: 27124059 Free PMC article.
-
Primary sclerosing cholangitis: overview and update.Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):611-9. doi: 10.1038/nrgastro.2010.155. Epub 2010 Oct 12. Nat Rev Gastroenterol Hepatol. 2010. PMID: 20938459 Review.
-
The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children.Hepatology. 2021 Mar;73(3):1074-1087. doi: 10.1002/hep.31393. Epub 2020 Dec 19. Hepatology. 2021. PMID: 32464706 Free PMC article.
-
Hepatobiliary complications of inflammatory bowel disease.Curr Gastroenterol Rep. 2011 Oct;13(5):495-505. doi: 10.1007/s11894-011-0213-9. Curr Gastroenterol Rep. 2011. PMID: 21773706 Review.
-
Primary sclerosing cholangitis.Can J Gastroenterol. 2008 Aug;22(8):689-98. doi: 10.1155/2008/824168. Can J Gastroenterol. 2008. PMID: 18701947 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources